Tucatinib(Tukysa)

Tucatinib is a prescription drug targeting the HER2 protein. It was approved
by the U.S. Food and Drug Administration (FDA) in April 2020. It should be used
strictly under medical supervision.

Target of Action

HER2 protein

Dosage and Administration

Route and frequency of administration of Tucatinib: Oral, once daily.

The dosage of Tucatinib should be adjusted according to the patient's actual condition. Please consult a doctor and follow medical advice.

Recommended reading: Dosage and administration of Tucatinib

Side Effects

Common side effects: Decreased appetite, low red blood cell count (anemia), etc.

Serious side effects: Diarrhea, liver problems, etc.

Reference article: Side effects of Tucatinib

Use in Specific Populations

Pregnancy: Tucatinib may cause harm to an unborn baby.

Breastfeeding: If you are breastfeeding or plan to breastfeed, do not breastfeed during treatment with Tucatinib and for 1 week after the last dose of Tucatinib.

Daily Precautions

1. Inform patients that the use of Tucatinib may cause severe diarrhea. Instruct patients on how to manage diarrhea and advise them to immediately inform their healthcare provider of any changes in bowel habits.

2. Inform the clinician of all current or planned concomitant treatments, including prescription drugs, over-the-counter medications, dietary supplements, or herbal products, as well as any coexisting medical conditions.

3. Inform patients that the use of Tucatinib may cause severe hepatotoxicity. They should immediately report to their healthcare provider any signs or symptoms of liver dysfunction.

from FDA，2023.01